$239 Million is the total value of First Light Asset Management, LLC's 65 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | ALLERGAN PLC SHS | $636,000 | +15.0% | 2,035 | 0.0% | 0.27% | -2.6% | |
| HUM | HUMANA INC | $632,000 | -0.3% | 3,540 | 0.0% | 0.26% | -15.3% | |
| UTHR | UNITED THERAPEUTICS CORP DEL | $598,000 | +19.4% | 3,820 | 0.0% | 0.25% | +1.2% | |
| BMY | BRISTOL MYERS SQUIBB CO | $570,000 | +16.1% | 8,290 | 0.0% | 0.24% | -1.6% | |
| ANTM | ANTHEM INC COM | $571,000 | -0.3% | 4,095 | 0.0% | 0.24% | -15.5% | |
| AET | AETNA INC NEW | $564,000 | -1.2% | 5,215 | 0.0% | 0.24% | -16.3% | |
| MYL | MYLAN N V | $529,000 | +34.3% | 9,775 | 0.0% | 0.22% | +13.8% | |
| NVS | NOVARTIS A G | $522,000 | -6.5% | 6,070 | 0.0% | 0.22% | -20.7% | |
| BDX | BECTON DICKINSON AND CO | $523,000 | +16.2% | 3,395 | 0.0% | 0.22% | -1.4% | |
| CELG | CELGENE CORP | $513,000 | +10.8% | 4,280 | 0.0% | 0.22% | -6.1% | |
| ENDP | ENDO INTL PLC | $500,000 | -11.5% | 8,161 | 0.0% | 0.21% | -25.1% | |
| STE | STERIS CORP | $477,000 | +16.1% | 6,330 | 0.0% | 0.20% | -1.5% | |
| LLY | LILLY ELI AND CO | $463,000 | +0.7% | 5,495 | 0.0% | 0.19% | -14.5% | |
| JNJ | JOHNSON AND JOHNSON | $392,000 | +9.8% | 3,820 | 0.0% | 0.16% | -6.8% | |
| AZN | ASTRAZENECA PLC | $386,000 | +6.9% | 11,360 | 0.0% | 0.16% | -9.0% | |
| AMGN | AMGEN INC | $378,000 | +17.4% | 2,330 | 0.0% | 0.16% | -0.6% | |
| STJ | ST JUDE MED INC | $374,000 | -2.1% | 6,055 | 0.0% | 0.16% | -16.9% | |
| MRK | MERCK N CO INC NEW | $349,000 | +7.1% | 6,610 | 0.0% | 0.15% | -9.3% | |
| MYGN | MYRIAD GENETICS INC | $338,000 | +15.4% | 7,820 | 0.0% | 0.14% | -2.1% | |
| PFE | PFIZER INC | $340,000 | +3.0% | 10,520 | 0.0% | 0.14% | -12.9% | |
| SNY | SANOFI-SYNTHELABO | $242,000 | -10.4% | 5,680 | 0.0% | 0.10% | -24.1% | |
| BIO | BIO RAD LABS INC | $232,000 | +3.1% | 1,675 | 0.0% | 0.10% | -12.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.